RU2020128838A - Композиции и способы для индуцирования передачи сигнала белка, содержащего трехсторонний мотив, 16 (trim16) - Google Patents

Композиции и способы для индуцирования передачи сигнала белка, содержащего трехсторонний мотив, 16 (trim16) Download PDF

Info

Publication number
RU2020128838A
RU2020128838A RU2020128838A RU2020128838A RU2020128838A RU 2020128838 A RU2020128838 A RU 2020128838A RU 2020128838 A RU2020128838 A RU 2020128838A RU 2020128838 A RU2020128838 A RU 2020128838A RU 2020128838 A RU2020128838 A RU 2020128838A
Authority
RU
Russia
Prior art keywords
nucleic acid
cell
cancer
trim16
arm region
Prior art date
Application number
RU2020128838A
Other languages
English (en)
Russian (ru)
Other versions
RU2020128838A3 (cg-RX-API-DMAC7.html
Inventor
Майкл Дж. Мл. ГЕЙЛ
Original Assignee
Юниверсити Оф Вашингтон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Вашингтон filed Critical Юниверсити Оф Вашингтон
Publication of RU2020128838A publication Critical patent/RU2020128838A/ru
Publication of RU2020128838A3 publication Critical patent/RU2020128838A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2020128838A 2018-02-02 2019-02-01 Композиции и способы для индуцирования передачи сигнала белка, содержащего трехсторонний мотив, 16 (trim16) RU2020128838A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625623P 2018-02-02 2018-02-02
US62/625,623 2018-02-02
PCT/US2019/016413 WO2019152884A1 (en) 2018-02-02 2019-02-01 Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling

Publications (2)

Publication Number Publication Date
RU2020128838A true RU2020128838A (ru) 2022-03-03
RU2020128838A3 RU2020128838A3 (cg-RX-API-DMAC7.html) 2022-07-14

Family

ID=67479930

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020128838A RU2020128838A (ru) 2018-02-02 2019-02-01 Композиции и способы для индуцирования передачи сигнала белка, содержащего трехсторонний мотив, 16 (trim16)

Country Status (9)

Country Link
US (1) US20210046168A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746088B1 (cg-RX-API-DMAC7.html)
JP (1) JP7409612B2 (cg-RX-API-DMAC7.html)
KR (1) KR102828978B1 (cg-RX-API-DMAC7.html)
CN (1) CN111836623A (cg-RX-API-DMAC7.html)
AU (1) AU2019215191B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015821A2 (cg-RX-API-DMAC7.html)
RU (1) RU2020128838A (cg-RX-API-DMAC7.html)
WO (1) WO2019152884A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
JP2022550454A (ja) * 2019-10-02 2022-12-01 ユニバーシティ オブ ワシントン B型肝炎ウイルス感染の治療のための組成物及び方法
EP4058581A1 (en) * 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
EP4112665A4 (en) * 2020-03-27 2024-04-10 Mitsui Chemicals, Inc. LIGHT-CURING COMPOSITION, CURED PRODUCT AND DENTAL PRODUCT
KR20240043747A (ko) 2021-07-02 2024-04-03 예일 유니버시티 암을 치료하기 위한 조성물 및 방법
JP2024532621A (ja) 2021-08-31 2024-09-05 イエール ユニバーシティ がんを治療するための組成物および方法
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Sars-cov-2 rnaワクチン組成物および使用方法
AU2023228912A1 (en) 2022-03-03 2024-09-19 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003218181A1 (en) 2002-03-15 2003-09-29 Multicell Immunotherapeutics, Inc. Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
JP2010500011A (ja) 2006-08-08 2010-01-07 ガンサー ハートマン 5’リン酸オリゴヌクレオチドの構造および使用
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Eduardo Nowill Alexandre agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9775894B2 (en) * 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
US10624964B2 (en) * 2015-05-01 2020-04-21 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs
CN117244049A (zh) * 2016-02-16 2023-12-19 哈佛学院院长等 病原体疫苗及其生产和使用方法

Also Published As

Publication number Publication date
EP3746088B1 (en) 2024-07-10
KR20200116976A (ko) 2020-10-13
KR102828978B1 (ko) 2025-07-02
WO2019152884A1 (en) 2019-08-08
EP3746088A1 (en) 2020-12-09
EP3746088C0 (en) 2024-07-10
JP2021512123A (ja) 2021-05-13
JP7409612B2 (ja) 2024-01-09
US20210046168A1 (en) 2021-02-18
EP3746088A4 (en) 2023-02-22
AU2019215191B2 (en) 2025-08-14
AU2019215191A1 (en) 2020-09-17
CN111836623A (zh) 2020-10-27
BR112020015821A2 (pt) 2021-03-09

Similar Documents

Publication Publication Date Title
JP2021512123A5 (cg-RX-API-DMAC7.html)
US20240066096A1 (en) pHLIP® peptide mediated epitope tethering at cell surfaces
WO2021147121A1 (zh) 修饰的免疫细胞及其应用
RU2007136026A (ru) Варианты ил-21
CA2361009A1 (en) Her-2/neu fusion proteins
JP2023539871A5 (cg-RX-API-DMAC7.html)
JP2021525549A5 (cg-RX-API-DMAC7.html)
JP2023510121A5 (cg-RX-API-DMAC7.html)
JP2024513559A5 (cg-RX-API-DMAC7.html)
Kawakatsu et al. Human carcinoma cells synthesize and secrete tenascin in vitro
WO2012144726A2 (ko) 폴로-유사 키나아제 1의 종양항원 단백질 또는 유전자
CN114302962A (zh) 特异性针对来源于ebv抗原的tcr构建体
JP2023523083A5 (cg-RX-API-DMAC7.html)
JP2022507373A5 (cg-RX-API-DMAC7.html)
US8802619B2 (en) Cancer vaccine
WO2017035251A1 (en) T cells modified to overexpress c-myb
RU2004122084A (ru) Пептиды для лечения рака, ассоциированного с папилломавирусом (hpv) человека, и других эпителиальных опухолей
CN107875376A (zh) 包含ny‑eso‑1的微泡、其制备方法及用途
FI3335725T3 (fi) Pds5a-epitooppeja immuuniteetin indusoijina
JP2024528029A5 (cg-RX-API-DMAC7.html)
JP2023502843A5 (cg-RX-API-DMAC7.html)
CN111118063B (zh) 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用
CN119770633A (zh) 一种改进型多肽肿瘤疫苗组成与应用
CN117797253A (zh) 一种能扩展t细胞抗原表位的肿瘤疫苗及其制备方法
US8207141B2 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof